News & Events

News & Events


DEA Just Said No to Rescheduling Cannabis: Why It Matters

Bookmark and Share

Justin E. Hobson authored an article titled “DEA Just Said No to Rescheduling Cannabis: Why It Matters.” The article discusses the U.S. Drug Enforcement Agency’s (DEA) recent denial of a petition to initiate proceedings to reschedule cannabis under the Controlled Substances Act, and also addresses the practical significance of scheduling.

Rescheduling cannabis from Schedule I to Schedule II requires acknowledgement from the DEA that cannabis has a currently accepted medical use in the U.S.  A substance having no currently accepted medical use and meeting other controlled substance criteria must be classified as a Schedule I substance.  In making the scheduling determination, the DEA is bound by scientific and medical recommendations from the U.S. Department of Health and Human Services (HHS).